Baidu
map

Pediatrics:IP-10与QFR-IT实验诊断结核病的灵敏度

2014-12-03 MedSci MedSci原创译

干扰素γ和IP-10释放实验都可以诊断结核病(tuberculosis,TB)。为了比较IP-10和QFT-IT(QuantIFERON-TB Gold In-tube)诊断TB的准确性,哥本哈根大学医学院的Line Lindebo Holm医生对坦桑尼亚地区TB感染的住院儿童展开调查,研究结果发表在近期的Pediatrics上。研究者对有TB症状的住院患儿分别使用QFT-IF和IP-10实验进行

干扰素γ和IP-10释放实验都可以诊断结核病(tuberculosis,TB)。

为了比较IP-10和QFT-IT(QuantIFERON-TB Gold In-tube)诊断TB的准确性,哥本哈根大学医学院的Line Lindebo Holm医生对坦桑尼亚地区TB感染的住院儿童展开调查,研究结果发表在近期的Pediatrics上。

研究者对有TB症状的住院患儿分别使用QFT-IF和IP-10实验进行检测,以确诊TB的成人作对照。
研究共纳入了平均年龄为3岁的203名儿童,这些儿童中有38%为HIV感染,36%的患儿年龄小于2岁,58%的患儿体重低于平均水平。

IP-10和QFT-IT实验的结果具有可比性,但是灵敏度低:对于确诊TB患儿检出率为33%,对于可能TB患儿检出率为29%。

两种检验方法的反应率很高:IP-10反应率为29%,QFT-IT反应率为26%。年龄小于2岁与检验方法的反应率具有相关性,IP-10的调整OR值为2.2,P=0.02,QFT-IT的调整OR值为2.4,P=0.01。TB暴露与阳性IP-10检验结果有相关性,调整OR值为3.6,P=0.01,但是与阳性QFT-IT检验结果没有明显相关性,调整OR值为1.4,P=0.52。对于102名成人,两种检验方法的灵敏度都是80%。

研究表明,尽管IP-10和QFT-IT检测坦桑尼亚成人TB的灵敏度高,但是检测儿童TB的灵敏度很低。两种检测方法都不能检测出幼儿的TB感染情况。所以不建议在TB流行地区用这两种方法检测住院儿童的TB感染情况。

原始出处:

Holm, L.L., et al., A Comparison of Interferon-gamma and IP-10 for the Diagnosis of Tuberculosis. Pediatrics, 2014. 134(6): p. e1568-75.

本文是MedSci原创编译整理,欢迎转载! 转载请注明来源并附原文链接。谢谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775901, encodeId=5bda1e759015f, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6838842412, createdName=respect, createdTime=Mon Feb 09 08:39:00 CST 2015, time=2015-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636975, encodeId=161e16369e52c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 25 23:39:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958394, encodeId=cac4195839465, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jan 10 22:39:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725684, encodeId=fbb01e25684d0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri May 22 04:39:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253939, encodeId=8d61125393937, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Dec 05 11:39:00 CST 2014, time=2014-12-05, status=1, ipAttribution=)]
    2015-02-09 respect
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775901, encodeId=5bda1e759015f, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6838842412, createdName=respect, createdTime=Mon Feb 09 08:39:00 CST 2015, time=2015-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636975, encodeId=161e16369e52c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 25 23:39:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958394, encodeId=cac4195839465, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jan 10 22:39:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725684, encodeId=fbb01e25684d0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri May 22 04:39:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253939, encodeId=8d61125393937, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Dec 05 11:39:00 CST 2014, time=2014-12-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1775901, encodeId=5bda1e759015f, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6838842412, createdName=respect, createdTime=Mon Feb 09 08:39:00 CST 2015, time=2015-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636975, encodeId=161e16369e52c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 25 23:39:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958394, encodeId=cac4195839465, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jan 10 22:39:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725684, encodeId=fbb01e25684d0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri May 22 04:39:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253939, encodeId=8d61125393937, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Dec 05 11:39:00 CST 2014, time=2014-12-05, status=1, ipAttribution=)]
    2015-01-10 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=1775901, encodeId=5bda1e759015f, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6838842412, createdName=respect, createdTime=Mon Feb 09 08:39:00 CST 2015, time=2015-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636975, encodeId=161e16369e52c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 25 23:39:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958394, encodeId=cac4195839465, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jan 10 22:39:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725684, encodeId=fbb01e25684d0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri May 22 04:39:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253939, encodeId=8d61125393937, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Dec 05 11:39:00 CST 2014, time=2014-12-05, status=1, ipAttribution=)]
    2015-05-22 feather89
  5. [GetPortalCommentsPageByObjectIdResponse(id=1775901, encodeId=5bda1e759015f, content=<a href='/topic/show?id=ede06694367' target=_blank style='color:#2F92EE;'>#灵敏度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66943, encryptionId=ede06694367, topicName=灵敏度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6838842412, createdName=respect, createdTime=Mon Feb 09 08:39:00 CST 2015, time=2015-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636975, encodeId=161e16369e52c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 25 23:39:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958394, encodeId=cac4195839465, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Jan 10 22:39:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725684, encodeId=fbb01e25684d0, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri May 22 04:39:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253939, encodeId=8d61125393937, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Dec 05 11:39:00 CST 2014, time=2014-12-05, status=1, ipAttribution=)]

相关资讯

Lancet: 1990~2013年艾滋病、肺结核和疟疾的全球发病率和死亡率

2000年的千年宣言中的千年发展目标(MDG)6使艾滋病、肺结核和疟疾得到了全球的特别关注。2013年度全球疾病负担研究为1990~2013年疾病评估提供了一个一致综合的的途径,并且这是评价千年宣言是否有快速进展的一个机会。该研究基于2013年全球疾病负担研究,对艾滋病、肺结核和疟疾的数据进行系统分析,得出全球、各地区、各国家的发病率和死亡率。为了评估艾滋病的发病率和死亡率,研究者基于一个对进行和

NEJM:Sirturo(Bedaquiline)能显著提高耐药肺结核治愈率

8月23日NEJM发表了J&J旗下杨森制药的Sirturo(Bedaquiline)治疗多耐药肺结核的长期跟踪结果。这是一个二期临床,共有160位患者参加。用药组和对照组都以标准疗法作为背景治疗。用药组前两周使用每日一次400毫克Sirturo,然后使用22周每周3次200毫克的维持剂量。结果在第120周用药组治愈率为58%,而对照组为32%,但用药组有10人死亡而对照组只有2人死亡。&n

NEJM: 高剂量的利福喷汀联合莫西沙星治疗肺结核

背景:目前治疗肺结核的治疗方案时间太长太复杂,需要新的治疗方案。方法:研究对象为初诊病人、涂片阳性和药物敏感的肺结核患者,随机分为3组。对照组的治疗方案为每天服用乙胺丁醇片、异烟肼、利福平和吡嗪酰胺2个月,接着每天服用异烟肼和利福平4个月;新的治疗方案为每天服用乙胺丁醇片、莫西沙星、利福平和吡嗪酰胺2个月,接着每周两次服用莫西沙星和900 mg利福喷汀2个月;另一个新的治疗方案为每天服用乙胺丁醇片

Lancet Infect Dis:开发出针对儿童的新型高特异性的肺结核血液检测技术

9月1日,一项发表在国际杂志Lancet Infectious Diseases上的研究报告中,来自瑞士的科学家通过研究开发了一种新型可靠的、针对儿童的高特异性的肺结核血液检测技术;这种新型的名为TAM-TB实验的检测技术是第一个可以用于检测阳性肺结核儿童的可靠免疫诊断法,其具有较高的特异性,可以对儿童是否患肺结核进行快测检测。 儿童患肺结核是全球一项比较严重的健康问题,尤其

NEJM:欲速则不达---肺结核治疗应该回归原点

    肺结核给全球健康带来极大威胁,目前每年约有800万的新感染病例以及130万的死亡病例。在缺乏疫苗保护的情况下,6个月的化疗作为控制药物敏感肺结核病的标准方案已经使用了30年之久。  标准的用药方案包括2个月的加强阶段(用药为rifampin, isoniazid, pyrazinamide 和ethambutol)和 4个月的持续阶段(用药为isonia

NEJM:大剂量利福喷汀配合莫西沙星有效治疗肺结核

背景:相比于目前的6个月每日给药的方案来讲肺结核的治疗方案要简短一些。 方法: 我们随机分配新诊断的,痰检阳性,非肺结核的患者到三种方案之一:其中对照组包括2个月乙胺丁醇、异烟肼、利福平、吡嗪酰胺每日给药以及随后4个月每日给药异烟肼和利福平;4个月的方案是将对照组中异烟肼的给药方案替换成每天服用莫西沙星为期2个月随之是莫西沙星和900毫克的利福喷汀联合使用每周2次为期2个月的方案;6个月的方案是

Baidu
map
Baidu
map
Baidu
map